TY - JOUR
T1 - Perspectives, fears and expectations of patients with gynaecological cancers during the COVID-19 pandemic
T2 - A Pan-European study of the European Network of Gynaecological Cancer Advocacy Groups (ENGAGe)
AU - Gultekin, Murat
AU - Ak, Sertac
AU - Ayhan, Ali
AU - Strojna, Aleksandra
AU - Pletnev, Andrei
AU - Fagotti, Anna
AU - Perrone, Anna Myriam
AU - Erzeneoglu, B Emre
AU - Temiz, B Esat
AU - Lemley, Birthe
AU - Soyak, Burcu
AU - Hughes, Cathy
AU - Cibula, David
AU - Haidopoulos, Dimitrios
AU - Brennan, Donal
AU - Cola, Edoardo
AU - van der Steen-Banasik, Elzbieta
AU - Urkmez, Esra
AU - Akilli, Huseyin
AU - Zapardiel, Ignacio
AU - Tóth, Icó
AU - Sehouli, Jalid
AU - Zalewski, Kamil
AU - Bahremand, Kiarash
AU - Chiva, Luis
AU - Mirza, Mansoor Raza
AU - Papageorgiou, Maria
AU - Zoltan, Novak
AU - Adámková, Petra
AU - Morice, Philippe
AU - Garrido-Mallach, Sonia
AU - Akgor, Utku
AU - Theodoulidis, Vasilis
AU - Arik, Zafer
AU - Steffensen, Karina D
AU - Fotopoulou, Christina
N1 - © 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
PY - 2021/1
Y1 - 2021/1
N2 - BACKGROUND: The impact of the COVID-19 pandemic on European gynaecological cancer patients under active treatment or follow-up has not been documented. We sought to capture the patient perceptions of the COVID-19 implications and the worldwide imposed treatment modifications.METHODS: A patient survey was conducted in 16 European countries, using a new COVID-19-related questionnaire, developed by ENGAGe and the Hospital Anxiety & Depression Scale questionnaire (HADS). The survey was promoted by national patient advocacy groups and charitable organisations.FINDINGS: We collected 1388 forms; 592 online and 796 hard-copy (May, 2020). We excluded 137 due to missing data. Median patients' age was 55 years (range: 18-89), 54.7% had ovarian cancer and 15.5% were preoperative. Even though 73.2% of patients named cancer as a risk factor for COVID-19, only 17.5% were more afraid of COVID-19 than their cancer condition, with advanced age (>70 years) as the only significant risk factor for that. Overall, 71% were concerned about cancer progression if their treatment/follow-up was cancelled/postponed. Most patients (64%) had their care continued as planned, but 72.3% (n = 892) said that they received no information around overall COVID-19 infection rates of patients and staff, testing or measures taken in their treating hospital. Mean HADS Anxiety and Depression Scores were 8.8 (range: 5.3-12) and 8.1 (range: 3.8-13.4), respectively. Multivariate analysis identified high HADS-depression scores, having experienced modifications of care due to the pandemic and concern about not being able to visit their doctor as independent predictors of patients' anxiety.INTERPRETATION: Gynaecological cancer patients expressed significant anxiety about progression of their disease due to modifications of care related to the COVID-19 pandemic and wished to pursue their treatment as planned despite the associated risks. Healthcare professionals should take this into consideration when making decisions that impact patients care in times of crisis and to develop initiatives to improve patients' communication and education.
AB - BACKGROUND: The impact of the COVID-19 pandemic on European gynaecological cancer patients under active treatment or follow-up has not been documented. We sought to capture the patient perceptions of the COVID-19 implications and the worldwide imposed treatment modifications.METHODS: A patient survey was conducted in 16 European countries, using a new COVID-19-related questionnaire, developed by ENGAGe and the Hospital Anxiety & Depression Scale questionnaire (HADS). The survey was promoted by national patient advocacy groups and charitable organisations.FINDINGS: We collected 1388 forms; 592 online and 796 hard-copy (May, 2020). We excluded 137 due to missing data. Median patients' age was 55 years (range: 18-89), 54.7% had ovarian cancer and 15.5% were preoperative. Even though 73.2% of patients named cancer as a risk factor for COVID-19, only 17.5% were more afraid of COVID-19 than their cancer condition, with advanced age (>70 years) as the only significant risk factor for that. Overall, 71% were concerned about cancer progression if their treatment/follow-up was cancelled/postponed. Most patients (64%) had their care continued as planned, but 72.3% (n = 892) said that they received no information around overall COVID-19 infection rates of patients and staff, testing or measures taken in their treating hospital. Mean HADS Anxiety and Depression Scores were 8.8 (range: 5.3-12) and 8.1 (range: 3.8-13.4), respectively. Multivariate analysis identified high HADS-depression scores, having experienced modifications of care due to the pandemic and concern about not being able to visit their doctor as independent predictors of patients' anxiety.INTERPRETATION: Gynaecological cancer patients expressed significant anxiety about progression of their disease due to modifications of care related to the COVID-19 pandemic and wished to pursue their treatment as planned despite the associated risks. Healthcare professionals should take this into consideration when making decisions that impact patients care in times of crisis and to develop initiatives to improve patients' communication and education.
KW - Adolescent
KW - Adult
KW - Aged
KW - Aged, 80 and over
KW - Anxiety/psychology
KW - COVID-19/epidemiology
KW - Depression/psychology
KW - Europe
KW - Fear/psychology
KW - Female
KW - Genital Neoplasms, Female/psychology
KW - Humans
KW - Middle Aged
KW - Pandemics
KW - SARS-CoV-2/isolation & purification
KW - Surveys and Questionnaires
KW - Young Adult
UR - http://www.scopus.com/inward/record.url?scp=85096674613&partnerID=8YFLogxK
U2 - 10.1002/cam4.3605
DO - 10.1002/cam4.3605
M3 - Journal article
C2 - 33205595
SN - 2045-7634
VL - 10
SP - 208
EP - 219
JO - Cancer Medicine
JF - Cancer Medicine
IS - 1
ER -